ALBUQUERQUE, N.M., March 19, 2026 (GLOBE NEWSWIRE)-- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software, services ...
Preparations underway to advance AP-101 into confirmatory Phase 3 clinical trial with initiation aimed for late 2026 ZURICH, March 19, 2026--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage ...
Iran did not rebuild its uranium enrichment capability following joint U.S.-Israeli strikes against its nuclear program last year, U.S. Director of National Intelligence (DNI) Tulsi Gabbard told a ...
Are you a step counter, aiming for 10,000 steps per day to stay healthy? Many studies have suggested you don't need to hit that mark to maintain good health and live longer. And now the largest study ...
ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis ...
AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
The United Nations' nuclear watchdog chief says he does not believe the war in Iran can entirely eliminate the nation's nuclear program, even if the main facilities are heavily damaged. And Iran ...
EQS-News: AL-S Pharma AG / Key word (s): Study results Additional Phase 2 Data of AL-S Pharma's Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results